Acrux Ltd (ACR) - Financial and Strategic SWOT Analysis Review

November 2021 | 39 pages | ID: A0E5E5D8E3EEN
GlobalData

Abstracts

Acrux Ltd (ACR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acrux Ltd (Acrux) is a pharmaceutical company that develops and commercializes generic and specialty topical pharmaceuticals. Its products are used for the treatment of fungal infection, endogenous testosterone and anaesthesia. The company's products include Its major products include testosterone topical solution and estradiol MDTS. Testosterone Topical Solution for treatment of adult males with no testosterone or low testosterone and Estradiol for treatment of moderate to severe hot flushes. Acrux has 15 products in generic topical portfolio. The company's major pipeline products include Jublia for treatment of fungal infection of the nail and EMLA cream for the treatment of topical anaesthetics. Acrux is headquartered in Brisbane, Victoria, Australia.

Acrux Ltd Key Recent Developments

Jun 04,2021: Acrux announces board appointment
May 31,2021: Acrux: Receipt of R&D tax incentive rebate – Overseas finding application for Acrux Pharma
Apr 30,2021: Receipt of R&D tax incentive rebate – Overseas finding application for Acrux Commercial
Oct 15,2020: Acrux: Receipt of R&D tax incentive rebate
Mar 20,2020: Acrux – COVID-19 Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Acrux Ltd - Key Facts
Acrux Ltd - Key Employees
Acrux Ltd - Key Employee Biographies
Acrux Ltd - Major Products and Services
Acrux Ltd - History
Acrux Ltd - Company Statement
Acrux Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Acrux Ltd - Business Description
Product Category: Other Revenue
Performance
Product Category: Revenue From Licensing Agreements
Performance
R&D Overview
Acrux Ltd - SWOT Analysis
SWOT Analysis - Overview
Acrux Ltd - Strengths
Acrux Ltd - Weaknesses
Acrux Ltd - Opportunities
Acrux Ltd - Threats
Acrux Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Acrux Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 04, 2021: Acrux announces board appointment
May 31, 2021: Acrux: Receipt of R&D tax incentive rebate – Overseas finding application for Acrux Pharma
Apr 30, 2021: Receipt of R&D tax incentive rebate – Overseas finding application for Acrux Commercial
Oct 15, 2020: Acrux: Receipt of R&D tax incentive rebate
Mar 20, 2020: Acrux – COVID-19 Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Acrux Ltd, Key Facts
Acrux Ltd, Key Employees
Acrux Ltd, Key Employee Biographies
Acrux Ltd, Major Products and Services
Acrux Ltd, History
Acrux Ltd, Subsidiaries
Acrux Ltd, Key Competitors
Acrux Ltd, Ratios based on current share price
Acrux Ltd, Annual Ratios
Acrux Ltd, Annual Ratios (Cont...1)
Acrux Ltd, Annual Ratios (Cont...2)
Acrux Ltd, Interim Ratios
Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Acrux Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Acrux Ltd, Performance Chart (2017 - 2021)
Acrux Ltd, Ratio Charts
Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Acrux Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021